Novel Personalized AMD and Diabetic Retinopathy Treatment

Willner Itamar, HUJI, Faculty of Science, The Institute of Chemistry



LifeSciences and BioTechnology   


Diagnostics, Age-Related Macular Degeneration, Diabetic Retinopathy

Current development stage

TRL 3- Initial POC demonstrated; Animal studies are under evaluation


Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) are leading causes of blindness in the Western world. Both are characterized by pathological angiogenesis in the various eye structures.

Current treatment for AMD and DR includes monthly intraocular injection of various anti-VEGF agents. Novel biological drug family based on nucleic acid-based ligands, aptamers, is proven for use in ophthalmology.

Although these new treatments are promising, they have severe limitations. Not only they involved complicated surgical procedure, but also they are performed without direct measurement of disease biomarkers in different patients. Therefore, there is still a high demand for more personalized and safer approach to improve efficiency and compliancy.

Our Innovation

Non-invasive method of personalized diagnosis and treatment of ocular disease, Age Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) using novel nanoparticle-mediated delivery of aptamers

Nanoparticles mediated penetration functioning on the same scale as ocular transport molecular processes holds promise of topical noninvasive patient compliant next generation of VEGF aptamer approach to fight AMD-induced blindness risks. 



  • Topical delivery
  • Personalized angiogenesis-regulated delivery to revolutionize aptamers drugs field


Diabetic retinopathy is among the key causes of legal blindness in working adult population. With overall prevalence of around 34% in the total diabetes population, the burden in form of direct and indirect management cost of diabetic retinopathy is humongous.





Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: